Date Title
Apr 19, 2017 Pluristem Reaches Milestone of 100 Granted Patents, Including Coverage of Leading Indications in Major Markets
Mar 30, 2017 Pluristem and Sosei CVC Advancing Towards Finalizing Joint Venture for the Commercialization of PLX-PAD in Japan
Mar 29, 2017 Pluristem Launches Co-CEO Structure and Appoints New CFO
Feb 13, 2017 Pluristem Reports Second Quarter Fiscal 2017 Highlights & Provides Calendar 2017 Outlook
Jan 25, 2017 Pluristem Announces Closing of Bought Offering and Underwriter’s Exercise in Full of Over-Allotment Option
Jan 22, 2017 Pluristem Increases Previously Announced Bought Deal Offering of Common Stock and Warrants to $15,000,000
Jan 19, 2017 Pluristem Announces Bought Deal Offering
Jan 17, 2017 Pluristem Receives Clearance from Germany to Initiate its Multinational Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing Approval
Jan 12, 2017 Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication
Jan 10, 2017 Pluristem’s Phase III Study of PLX-PAD Cells for the Treatment of Critical Limb Ischemia Cleared by U.S. FDA